Evaluation of Long-Acting Injectable (LAI) and Teen Clubs in Adolescents (ATTUNE).

Launched by AFRICA HEALTH RESEARCH INSTITUTE · Dec 3, 2024

Keywords

ClinConnect Summary

The ATTUNE trial is a study looking at how well peer support and a special type of HIV treatment called long-acting injectable antiretroviral therapy (ART) work for teenagers living with HIV in South Africa. The goal is to see if these approaches help young people stay healthy by keeping their HIV under control and ensuring they continue to receive care. The trial is not yet recruiting participants, but it aims to include adolescents aged 12 to 19 who have been diagnosed with HIV, are aware of their status, and have been receiving treatment for at least six months.

To join the study, participants must be able to read or speak one of the local languages, such as English or isiZulu, and they will need permission from a parent or guardian. Participants can expect to receive support from peers who understand their situation, as well as access to the long-acting injectable treatment. This trial is important because it focuses on improving the health and care of young people with HIV, helping them to lead healthier lives.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged between 12 - 19, at enrolment
• • Living with HIV
• • Aware of their HIV status
• • Receiving ART for at least six months
• • Able to read and/or speak English, isiZulu, Sepedi, Afrikaans, Xhosa, or Sesotho
• • Willing and able to consent to study activities
• • Willing and able to get parental consent for study activities
• • (Stage 1, objective 2 only) Age ≥ 18 years and Caregiver of an adolescent with HIV
• • (Stage 1, objective 2 only) Age ≥ 18 years and provides clinical services or is a policy maker involved in adolescents with HIV
• Exclusion Criteria:
• • Inability to read and/or speak English, isiZulu, Sepedi, Afrikaans, Xhosa, or Sesotho
• • Severe mental or physical illness preventing participation in informed consent activities.